BXPHARMA Stock Overview
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh.
Beximco Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||৳150.20|
|52 Week High||৳255.40|
|52 Week Low||৳140.70|
|1 Month Change||-0.40%|
|3 Month Change||-9.08%|
|1 Year Change||-22.46%|
|3 Year Change||100.75%|
|5 Year Change||55.72%|
|Change since IPO||1,004.96%|
Recent News & Updates
|BXPHARMA||BD Pharmaceuticals||BD Market|
Return vs Industry: BXPHARMA underperformed the BD Pharmaceuticals industry which returned -5.2% over the past year.
Return vs Market: BXPHARMA underperformed the BD Market which returned -11.4% over the past year.
|BXPHARMA Average Weekly Movement||4.0%|
|Pharmaceuticals Industry Average Movement||3.8%|
|Market Average Movement||4.7%|
|10% most volatile stocks in BD Market||6.5%|
|10% least volatile stocks in BD Market||2.5%|
Stable Share Price: BXPHARMA is not significantly more volatile than the rest of BD stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BXPHARMA's weekly volatility (4%) has been stable over the past year.
About the Company
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids.
Beximco Pharmaceuticals Fundamentals Summary
|BXPHARMA fundamental statistics|
Is BXPHARMA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BXPHARMA income statement (TTM)|
|Cost of Revenue||৳17.90b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||12.86|
|Net Profit Margin||17.04%|
How did BXPHARMA perform over the long term?See historical performance and comparison
2.3%Current Dividend Yield
Is BXPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BXPHARMA?
Other financial metrics that can be useful for relative valuation.
|What is BXPHARMA's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does BXPHARMA's PE Ratio compare to its peers?
|BXPHARMA PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
BEACONPHAR Beacon Pharmaceuticals
SQURPHARMA Square Pharmaceuticals
ACMELAB ACME Laboratories
BXPHARMA Beximco Pharmaceuticals
Price-To-Earnings vs Peers: BXPHARMA is good value based on its Price-To-Earnings Ratio (11.7x) compared to the peer average (26.3x).
Price to Earnings Ratio vs Industry
How does BXPHARMA's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: BXPHARMA is good value based on its Price-To-Earnings Ratio (11.7x) compared to the BD Pharmaceuticals industry average (20.2x)
Price to Earnings Ratio vs Fair Ratio
What is BXPHARMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||11.7x|
|Fair PE Ratio||16.1x|
Price-To-Earnings vs Fair Ratio: BXPHARMA is good value based on its Price-To-Earnings Ratio (11.7x) compared to the estimated Fair Price-To-Earnings Ratio (16.1x).
Share Price vs Fair Value
What is the Fair Price of BXPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BXPHARMA (BDT150.2) is trading below our estimate of fair value (BDT153.98)
Significantly Below Fair Value: BXPHARMA is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Beximco Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BXPHARMA's forecast earnings growth (13.1% per year) is above the savings rate (3.6%).
Earnings vs Market: BXPHARMA's earnings (13.1% per year) are forecast to grow faster than the BD market (11.5% per year).
High Growth Earnings: BXPHARMA's earnings are forecast to grow, but not significantly.
Revenue vs Market: BXPHARMA's revenue (15% per year) is forecast to grow faster than the BD market (9.1% per year).
High Growth Revenue: BXPHARMA's revenue (15% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BXPHARMA's Return on Equity is forecast to be low in 3 years time (14%).
Discover growth companies
How has Beximco Pharmaceuticals performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BXPHARMA has high quality earnings.
Growing Profit Margin: BXPHARMA's current net profit margins (17%) are higher than last year (16.2%).
Past Earnings Growth Analysis
Earnings Trend: BXPHARMA's earnings have grown significantly by 21% per year over the past 5 years.
Accelerating Growth: BXPHARMA's earnings growth over the past year (25.3%) exceeds its 5-year average (21% per year).
Earnings vs Industry: BXPHARMA earnings growth over the past year (25.3%) exceeded the Pharmaceuticals industry 22.9%.
Return on Equity
High ROE: BXPHARMA's Return on Equity (12.9%) is considered low.
Discover strong past performing companies
How is Beximco Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BXPHARMA's short term assets (BDT17.9B) exceed its short term liabilities (BDT12.5B).
Long Term Liabilities: BXPHARMA's short term assets (BDT17.9B) exceed its long term liabilities (BDT8.8B).
Debt to Equity History and Analysis
Debt Level: BXPHARMA's net debt to equity ratio (24.2%) is considered satisfactory.
Reducing Debt: BXPHARMA's debt to equity ratio has increased from 16.6% to 25.9% over the past 5 years.
Debt Coverage: BXPHARMA's debt is well covered by operating cash flow (52.4%).
Interest Coverage: BXPHARMA's interest payments on its debt are well covered by EBIT (8.1x coverage).
Discover healthy companies
What is Beximco Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BXPHARMA's dividend (2.33%) is higher than the bottom 25% of dividend payers in the BD market (1.2%).
High Dividend: BXPHARMA's dividend (2.33%) is low compared to the top 25% of dividend payers in the BD market (3.87%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, BXPHARMA has been paying a dividend for less than 10 years.
Growing Dividend: BXPHARMA's dividend payments have increased, but the company has only paid a dividend for 8 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (27.2%), BXPHARMA's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (49.7%), BXPHARMA's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Nazmul Hassan, MP has been the Managing Director at Beximco Pharmaceuticals Limited since May 2009. Mr. Hassan served as the Managing Director of Shinepukur Ceramics Limited until November 14, 2013. Mr...
Experienced Management: BXPHARMA's management team is seasoned and experienced (13.3 years average tenure).
Experienced Board: BXPHARMA's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Beximco Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: Beximco Pharmaceuticals Limited
- Ticker: BXPHARMA
- Exchange: DSE
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ৳67.006b
- Shares outstanding: 446.11m
- Website: https://www.beximcopharma.com
Number of Employees
- Beximco Pharmaceuticals Limited
- 19 Dhanmondi R/A
- Road No. 7
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/12 00:00|
|End of Day Share Price||2022/08/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.